Reporting on Adverse Clinical Events, 2018

DOI: 10.1177/0069477018809684

Keywords: Acetaminophen (281),Acetazolamide (286),Advanced Melanoma Treatment (283),Ciprofloxacin (289),Denosumab (285),Dexamethasone, Intravitreal (287),Fondaparinux (276),Levofloxacin (284),Mometasone Furoate (277),Pen Needles (282),Protein Kinase Inhibitors (280),Proton Pump Inhibitors (278),Rituximab (279),Tizanidine (289),Valsartan (288)

Full-Text